Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms
Journal of Antimicrobial Chemotherapy · 03.06.2026 · 81 (7)
DOI: 10.1093/jac/dkag214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 19.06.2026. Verfasst von Xin Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Cefoperazone, Sulbactam, Anti-Bacterial Agents, Neutropenia. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Shanghai Talent Awards, Shanghai Science and Technology Innovation Action Plan.
Abstract (Originalsprache)
Objectives
Cefoperazone-sulbactam, a β-lactam/β-lactamase inhibitor combination, is widely used against ESBL-producing Gram-negative pathogens. This study investigated the in vivo pharmacokinetics/pharmacodynamics (PK/PD) of 1:1 and 2:1 cefoperazone-sulbactam formulations in neutropenic murine thigh and lung infection models.
Methods
Eleven ESBL-producing Gram-negative isolates with varying MICs were used to establish murine thigh and lung infection models. The plasma and epithelial lining fluid (ELF) pharmacokinetics of cefoperazone and sulbactam were evaluated over a wide dose range. Five dose-fractionation experiments were conducted to identify the PK/PD index most correlated with efficacy, and dose–escalation to determine PK/PD targets.
Results
All isolates exhibited cefoperazone MICs ≥ 64 mg/L, reduced by 8- to 16-fold by sulbactam at a 1:1 or 2:1 ratio. Cefoperazone and sulbactam showed linear pharmacokinetics across the dose range, well described by a two-compartmental model. Plasma protein binding was 57% for cefoperazone and 3% for sulbactam. ELF penetration was 0.12 for cefoperazone and 0.21 for sulbactam, which were used to determine the ELF-based targets. PK/PD targets reflecting the primary active component against each pathogen were reported. Cefoperazone %fT > MIC was used as the PK/PD index for E. coli and K. pneumoniae, the magnitude for 1-log10 cfu bacterial reduction was 50.3% (1:1) and 51.3% (2:1) in the thigh infection model, 52.4% (1:1) and 75.6% (2:1) in the lung infection model. For A. baumannii, sulbactam was identified as the primary active component, and the 1-log10 cfu %fT > MIC target for sulbactam was 68.7%.
Conclusions
Cefoperazone-sulbactam demonstrated strong in vivo antibacterial activity against the 11 tested isolates. This study established PK/PD targets under varied conditions, providing a valuable foundation for optimizing the clinical application of cefoperazone-sulbactam.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Key Laboratory of Antibiotic Clinical Pharmacology of the National Health Commission, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D, Huashan Hospital, Fudan University, Shanghai 200040, China.
- Professional Technical Service Platform for Comprehensive Preclinical Pharmacodynamic Evaluation and Clinical Translation of Antibacterial Agents, Huashan Hospital, Fudan University, Shanghai200040, China.
- Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China.
- PfizerPharmaceutical Ltd., Clinical Pharmacology, Development China, Beijing 100027, China.
ORCID-Profile: Yuancheng Chen, Jing Zhang
Förderung
- Shanghai Talent Awards
- Shanghai Science and Technology Innovation Action Plan
Zitieren
APA
Li, X., Li, Y., Chen, Y., Cong, S., Guo, B., Liu, X., Huang, Z., & Zhang, J. (2026). Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms. Journal of Antimicrobial Chemotherapy, 81(7). https://doi.org/10.1093/jac/dkag214
Vancouver
Li X, Li Y, Chen Y, Cong S, Guo B, Liu X, et al. Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms. Journal of Antimicrobial Chemotherapy. 2026;81(7). doi:10.1093/jac/dkag214
BibTeX
@article{Li2026,
author = {Li, Xin and Li, Yi and Chen, Yuancheng and Cong, Shuangchen and Guo, Beining and Liu, Xiaofen and Huang, Zhiwei and Zhang, Jing},
title = {Pharmacokinetics and pharmacodynamics of cefoperazone/sulbactam in neutropenic murine lung and thigh infection models against Gram-negative organisms},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
volume = {81},
number = {7},
doi = {10.1093/jac/dkag214}
}
EUVIMED